DOW JONES NEWSWIRES
Mylan Inc. (MYL) said the U.S. Food and Drug Administration
found no deficiencies in a Morgantown, W.Va., plant that had been
the subject of media reports that questioned its quality
control.
Last month, the Pittsburgh Post-Gazette reported that
generic-drug maker Mylan had launched an internal probe to
investigate whether workers at the plant had been routinely
overriding computer-generated warnings about the drugs being
produced at the plant. The newspaper cited an internal report and
had other experts review the report and call it a significant
problem.
Chief Executive Robert Coury has blasted the reporting in the
article and said it contained allegations that were "false,
misleading and unfounded."
"The baseless speculation that was caused by a highly
irresponsible and sensational news article with a biased agenda was
entirely unnecessary," Coury said Thursday.
Mylan's shares were up 3.5% at $14.07.
- By Kerry Grace Benn, Dow Jones Newswires; 212-416-2353;
kerry.benn@dowjones.com